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ABSTRACT 
Crimean-Congo haemorrhagic fever (CCHF) disease in humans shows a spectrum of 
severity, from mild to acute. The pathogenesis of this and other viral haemorrhagic fevers 
(VHF) is associated with alteration of vascular barrier function and haemorrhage, but the 
specific underlying mechanism is unknown. This thesis examines the progression of the 
disease, in particular virus-host cell interactions and how CCHFV modulates the function of 
both Type I IFN response and apoptotic pathways. Programmed cell death and regulation of 
apoptosis in response to viral infection is an important factor for host or virus survival. In order 
to establish viral infection and to keep the virus contagious, it is also important to evade 
antiviral responses such as Type I IFN response.  
An initial study showed that replicating CCHFV delays the Type I IFN response, possibly by 
interfering with the activation pathway of IRF-3. A second study revealed that the coding 
sequence of the S segment of CCHFV contains a proteolytic cleavage site, DEVD, which is 
conserved in all CCHFV strains. By using different recombinant expression systems and site-
directed mutagenesis, it was demonstrated that this motif is subject to caspase cleavage. It 
was also demonstrated that CCHFV nucleocapsid (N) protein is cleaved into a 30-kDa 
fragment while caspase activity is induced during infection and that CCHFV infection induces 
caspase-3-dependent apoptosis at late post infection. Using caspase inhibitors and cells 
lacking caspase-3, it was shown that the cleavage of N protein is caspase-3-dependent. The 
inhibition of apoptosis induced progeny viral titres.  
A study examining the crystal structures of CCHFV N revealed two distinct forms, an 
oligomeric form comprised of double antiparallel superhelices and a monomeric form. The 
head-to-tail interaction of the stalk region of one CCHFV N subunit and the base of the globular 
body of the adjacent subunit stabilises the helical organisation of the oligomeric form of 
CCHFV N. It also masks the conserved caspase-3 cleavage site present at the tip of the stalk 
region from host cell caspase-3 interaction and cleavage. Incubation with primer-length 
ssRNAs revealed the crystal structure of CCHFV N in its monomeric form, which is similar to 
a recently published structure. The conformational change in CCHFV N upon 
deoligomerisation results in exposure of the caspase-3 cleavage site and subjects CCHFV N 
to caspase-3 cleavage. Mutations of this cleavage site inhibit cleavage by caspase-3 and 
result in enhanced viral polymerase activity. These structural findings extend current 
knowledge regarding CCHFV N structure. Based on the high degree of structural similarity 
between CCHFV and LASV N proteins, they may have an ancestor in common.  
A final study showed that CCHFV has strategies for interplaying with apoptosis pathways, 
thereby regulating the caspase cascade. There were indications that CCHFV suppresses 
caspase activation at early stages of the CCHFV replication cycle, which perhaps benefits the 
establishment of infection. Furthermore, the host cellular response at late post infection 
appears to induce host cellular pro-apoptotic molecules through the death receptor pathway. 
External host-derived stimuli probably initiate the apoptotic process and the route continues 
either by crosstalk between the death receptor and mitochondria routes, or separately. 
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INTRODUCTION 
 
ZOONOSES 
Zoonotic diseases are caused by various pathogens. Human contact and exposure to both 
animals and arthropods form the basis of how zoonotic pathogens are transmitted. In some 
cases pathogens are transmitted by vectors such as rodents, mosquitos, sandflies, midges 
and ticks, which can carry the organism and thereby allow further transmission to different 
species. Diseases transmitted by vectors are known as vector-borne diseases. Vectors can 
be introduced to new geographical areas by: i) animal movements (shipment of livestock or 
migratory birds) or ii) changes in climate and environment (Woolhouse, Haydon et al. 2005). 
After mosquitos, ticks are the next most common vector within the arthropods and can 
transmit a wide range of pathogens (Edlow 2008). Important contributions to increased 
transmission of tick-borne diseases are often observed when humans accidently enter an 
endemic region or when climate change in the form of milder winters and warm autumns leads 
to an increase in mean temperature, allowing ticks to molt faster between different life cycle 
stages (larvae-nymph-adult). This increases the survival rate of ticks and can potentially 
enhance circulation of pathogens within the tick population (Gray, Dautel et al. 2009). 
Environmental changes such as increased area of forest and bush land also contribute, by 
increasing the habitat available for both ticks and larger hosts. Other important factors are a 
higher number of wildlife, due to decreased hunting activities, which can lead to a potential 
increase in transmission of the virus (Papa, Velo et al. 2009). In the absence of any 
commercial vaccine, prevention of disease relies on good awareness of the links between 
virus, vector and host and of the potential risk for further viral spread to humans, including 
human-to-human transmission. It also relies on rapid identification, in order to confirm infection 
(Figure 1). 
 
 
 
 2 
 
 
Fig 1. Prevention of CCHF disease relies on good awareness of the links between virus, vector and host and of the 
potential risk for further viral spread to humans, including human-to-human transmission. It also relies on rapid 
identification, in order to confirm infection. 
Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne viral infection of humans. The 
CCHF virus, disease or prevalence of antibodies has been reported across a wide 
geographical area from western China to the Middle East, Balkans and Africa (Ergonul 
2006). Humans are the only known host to develop disease after exposure to the virus. The 
virus can be transmitted by viraemic blood or tissues from patients or by livestock. However, 
exposure to infectious tick bites seems to be the more common transmission route for 
humans. There appears to be a connection between the incidence of tick-borne disease, in 
general terms, and profession. High-risk groups include farmers, veterinarians and forestry 
workers, i.e. groups regularly exposed to ticks, which results in an elevated risk of tick bites 
and thereby also disease (Jones, Garman et al. 2002). Nosocomial infections place 
healthcare workers in danger, especially when sick patients have not received a correct 
diagnosis.  
CCHF disease in humans shows a spectrum of severity, from mild to critical. The 
pathogenesis of CCHF and other viral haemorrhagic fevers (VHF) has not yet been clearly 
explained, but appears to be associated with alteration of vascular barrier function, defects 
in intrinsic coagulation cascade and haemorrhage. These are most probably due to a 
combination of several factors from the interaction between virus and host cells (Ergonul 
2006). 
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CRIM-CONGO HEMORRHAGIC FEVER VIRUS 
 
VIRUS CLASSIFICATION 
CCHFV is a member of the family Bunyaviridae, genus Nairovirus. In total, the Bunyaviridae 
family consists of the genera Orthobunyavirus, Hantavirus, Phlebovirus, Tospovirus and 
Nairovirus. CCHFV and all other bunyaviruses except the tospoviruses are zoonotic 
pathogens transmitted by different arthropods in humans and animals. The genus Nairovirus 
consists of over 30 different viruses, further divided into seven serogroups, but only three 
members cause disease in humans. These are CCHFV, which is considered to be the most 
important human pathogen among the nairoviruses, Dugbe virus (DUGBV) and Nairobi sheep 
disease virus (NSDV) (Elliott 1997, Elliott 2009). Another member of the nairoviruses, Hazara 
virus, a member of the Crimean-Congo haemorrhagic fever serogroup, but is non-pathogenic 
for humans. It is classified as risk class 2, whereas CCHFV is risk class 4 but it shares 
similarities with CCHFV and therefore might be an interesting model for studying CCHFV.  
VIRUS STRUCTURE, GENOME ORGANIZATION AND REPLICATION 
CCHF viruses are viral particles with a spherical envelope derived from host cellular 
membrane. The viral genome consists of three single-stranded RNA segments of negative 
sense referred to as the small (S), medium (M) and large segment (L) (Figure 2) 
Figure 2. Schematic diagram of the structure of Crimean-Congo haemorrhagic virus (CCHV) (I Andersson) 
S- segment 
L- segment 
M- segment 
5´ 
5´ 
5´ 1,7 kb 
5,4 kb 
12 kb 
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All three segments contain one open reading frame (ORF) flanked by a non-coding region 
(NTR/UTR) with partially complementary nucleotids at the end. The S segment encodes for 
nucleocapsid protein (N) which appears to be multifunctional. Besides protecting the viral RNA 
by encapsidation, it also participates in viral transcription and replication and is involved in host 
cellular processes (Elliott 1990, Andersson, Bladh et al. 2004, Andersson, Simon et al. 2004, 
Simon, Johansson et al. 2009, Karlberg, Tan et al. 2011). The M segment encodes for 
glycoproteins (Gn, Gc) which protrude through the viral lipid envelope and mediate virus host 
cell attachment and entry. 
RNA-dependent RNA polymerase (RdRp), which is encoded by the L segment, is necessary 
to initiate transcription and replication. The L segment of CCHFV and other nairoviruses is 
uniquely large compared with that in other bunyaviruses and contains a ovarian tumour 
protease domain (OTU), which has been suggested to be involved in cellular anti-viral 
mechanisms (Frias-Staheli, Giannakopoulos et al. 2007, Bergeron, Albarino et al. 2010). Each 
RNA segment is individually flanked by terminal noncoding regions (NTR/UTR), conserved 
between each RNA segment. Within all nairoviruses, these contain partial complementary 
nucleotides which form circular RNAs referred to panhandle structures. Using a mini-replicon 
based assay, it has been demonstrated that terminal non-coding regions contain promoter 
elements necessary for the transcription, replication and encapsidation of each RNA segment 
(Elliott 1990, Marriott and Nuttall 1992, Flick, Flick et al. 2003).  
The receptor for CCHF virus-host cell tropism has not yet been identified, but has been 
speculated to be a very common receptor or several receptors. Viral glycoproteins mediate 
the viral attachment step and CCHFV enters through endocytosis (Simon, Johansson et al. 
2009). The acidic environment is believed to induce the conformational change in the viral 
glycoproteins needed for fusion of viral and cellular membranes, which leads to the release of 
viral ribounucleocapsids (RNPs) into the cytoplasm, followed by viral transcription of the 
polymerase. Viral RNA serves as a template for both complementary RNA (cRNA) and 
messenger RNA (mRNA) synthesis and cRNA serves as a template for new viral genomes 
(vRNA). Shortly after transcription, viral proteins are synthesized on ribosomes, with 
nucleocapsid protein being the most abundantly synthesized protein in infected cells. 
Glycoproteins are translated in endoplasmic reticulum (ER), processed and transported to the 
Golgi complex. nucleocapsid protein, polymerase and newly synthesized vRNA form the 
RNPs and the assembly and maturation processes of progeny virus occur in the Golgi 
compartment with glycoproteins incorporated (Sanchez, Vincent et al. 2002). Actin filaments 
placed within the inner surface of the host cellular membrane play an important role in 
transporting nucleocapsid protein to the site of assembly, followed by vesicle transport to the 
cellular membrane where progeny viruses are released into the extracellular space (Elliott 
1990, Andersson, Simon et al. 2004). 
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EPIDIMIOLOGY; OCCURRENCE AND TRANSMISSION 
–Occurrence 
Confirmed CCHF human cases have been reported in south-eastern Europe (Albania, 
Bulgaria, Greece, Kosovo and Turkey), as well as in the Middle East, Asia and Africa 
(Maltezou, Andonova et al. 2010, Mertens, Schmidt et al. 2013). Most recently, viral RNA has 
been found in ticks in Spain (Estrada-Pena, Palomar et al. 2012, Estrada-Pena, Ruiz-Fons et 
al. 2013). 
–Transmission 
CCHFV is maintained and transmitted by members of the family of Ixodid ticks, particularly the 
genus Hyalomma (Hoogstraal 1979, Shepherd, Swanepoel et al. 1989, Whitehouse 2004). 
Ticks undergo different stages of their life cycle: beginning from egg, larva, nymph and as an 
adult (Fig.3). CCHF virus has been isolated from all stages of the tick life cycle, i.e. that 
transmission may occur both from adult female to egg (vertical) and from larvae to adult 
(horisontal). Since the life cycle of Ixodid ticks is approximately 2 years, an infected tick can 
serve as a reservoir for CCHFV by maintaining infection during colder periods and later re-
introduce the virus when temperatures rise. 
In nature, CCHFV circulates in an enzootic tick-vertebrate-tick cycle in which immature ticks, 
larvae, need to ingest a blood meal before they can molt to nymphs the next stage of 
development. Immature ticks feed on smaller animals, while adult ticks also feed on larger 
animals (Hoogstraal 1979) (Figure 3).  
 6 
 
 
 
Fig. 3. Life cycle of the Crimean-Congo hemorrhagic fever virus. Hard ticks are both a reservoir and vector for the 
CCHF virus. The ticks feed on wild and domestic animals (http.//www.cdc.gov) 
 
Ticks spread CCHFV to animals, wild and domestic, which develop a transient viraemia 
without any signs of illness. In areas where both small (rodents, hares) and large animals 
(sheep, cattle) are abundant, the virus can circulate unnoticed, with human cases occurring 
only occasionally. In contrast, in regions that have many small animals but few large animals, 
any humans who enter the area may be actively hunted by questing, resulting in a large 
number of infections (Bente, Forrester et al. 2013). This is illustrated by the outbreak of CCHF 
in Crimea in 1944, during World War II. Due to enemy occupation hunting activities decreased. 
As a result, the hare population increased enormously, which in turn led to an increase in the 
tick population. Reoccupation by soldiers led to humans accidentally entering the tick-
vertebrate-tick transmission cycle, which resulted in a outbreak of CCHF (Hoogstraal 1979). 
Handling livestock and/or contact with blood or tissue from infected animals during the 
slaughter process increases the risk of transmission of CCHFV. Another risk behaviour which 
has been identified as a source of infection is tick-crushing play by children in villages in 
endemic areas (prof. Z. Vatansever, pers. comm.). In addition to tick exposure, human-to-
human transmission can place e.g. healthcare workers in danger when caring for patients 
without a proper diagnosis (Shepherd, Swanepoel et al. 1985, Whitehouse 2004, Naderi, 
Sarvghad et al. 2011) .  
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DISEASE PROGRESSION 
The manifestation of the disease is rapid and can be divided into an incubation, pre-
haemorrhagic, haemorrhagic and, among survivors, convalescence phase (Figure 4).  
 
Figure 4. Course of Crimean-Congo haemorrhagic fever (CCHF) infection 
 
The incubation period is usually short and varies between a few days after viral exposure up 
to one week. There seems to be a correlation between incubation period, viral dose and 
disease severity. Furthermore, the transmission route appears to be important. Viraemia is 
suggested to develop faster if the patient has been exposed to a tick bite compared with a 
nosocomial infection (Swanepoel, Shepherd et al. 1987, Ergonul 2006, Cevik, Erbay et al. 
2007). Following incubation, the patient enters the pre-haemorrhagic phase, which is 
characterized by fever, vomiting, headache, fatigue and weakness. During this period the 
potential risk of human-to-human transmission is great, placing e.g. relatives, those caring for 
the sick member of the family or healthcare workers in danger, especially if the patient has not 
received an accurate diagnosis. The haemorrhagic period is short and is characterized by 
haemorrhagic manifestations appearing on mucus membranes and on the skin, and in this 
phase the patient may start to bleed from various sites (Whitehouse 2004, Ergonul 2006). 
According to the literature, death occurs 6-10 days after the patient first develops clinical signs 
and is due to organ failure caused by loss of blood, anaemia, dehydration and shock 
(Swanepoel, Gill et al. 1989). The convalescence period among survivors involves temporary 
symptoms such as weakness, confusion etc. (Hoogstraal 1979, Schnittler and Feldmann 
2003) 
Viremia
Fever, headache, 
vomiting
Bleedings
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The level of viraemia can be used as a prognostic marker. A high level of viral RNA (> 1.109 
genomes per mL plasma) early during infection is more frequently associated with a fatal 
outcome (Cevik, Erbay et al. 2007).  
Another marker predicting the prognosis of the disease is the development of a humoral 
response, since fatal cases show little evidence of development of a protective IgG antibody 
response (Hoogstraal 1979, Ergonul 2006). 
 
PATHOGENESIS OF DISEASE  
The mechanism behind the pathogenesis of CCHF is not completely understood, but is 
associated with alteration of vascular barrier function and haemorrhage, most probably due to 
a combination of several factors. 
Animal studies on Ebola haemorrhagic fever virus, which shares clinical features with CCHF, 
suggest that release of pro-inflammatory cytokines by the host response contributes to altered 
vascular function, hypotension, shock and organ failure (Schnittler and Feldmann 2003, 
Feldmann and Geisbert 2011). 
Endothelial cells are considered to be the major target of CCHFV. Endothelial cells line the 
inner surface of blood vessels and represent a barrier between blood and tissue. In vivo 
studies have provided evidence of CCHFV viral antigen and RNA in endothelial cells from liver 
and spleen (Bereczky, Lindegren et al. 2010, Zivcec, Safronetz et al. 2013). However, those 
studies were performed at time of death.  
In general, CCHF patients show abnormal function of the coagulation system and leakage of 
erythrocytes and plasma through the vascular epithelium into the tissue, which contributes to 
hypotension and in severe cases can lead to shock and organ failure (Burt, Swanepoel et al. 
1997). Other symptoms include enlarged liver and spleen, elevated plasma level of liver 
enzymes, platelet shortage and prolonged bleeding times (Hoogstraal 1979). 
Exposure to an infected tick bite seems to be the most common infection route for humans 
and in this case the first barrier overcome is the epithelium. This is followed by viral entry and 
release into endothelial cells, which leads on to viral spread in the bloodstream (Jones, 
Garman et al. 2002, Whitehouse 2004). In animal models, it has been demonstrated that early 
viral replication occurs in the blood, liver and spleen and thereafter spreads to the lung and 
kidney and can later also disseminate to the brain (Bente, Alimonti et al. 2010).   
The dissemination route of CCHFV has not completely been determined, but it has been 
suggested that amplification of the virus in macrophages and dendritic cells (antigen 
presenting cells) might contribute to increased levels of released cytokines, but also facilitate 
 9 
 
transmission of the virus to local lymph nodes, the spleen, the liver and the systemic circulation 
(Martinez, Leung et al. 2012). 
Infection leads to degradation or dysfunction of endothelial cells, but it is not known whether 
this is caused by virus-mediated host factors, by the virus infection itself or a combination of 
both (Peters and Zaki 2002, Ergonul 2006). Activation of endothelial cells is critical in starting 
immune reactions and activation of intrinsic coagulation cascade. Altered vascular function 
helps to enhance movement of circulating leucocytes from the sites of infection, thereby 
starting an inflammatory process (Weber and Mirazimi 2008). 
Infection and activation of DCs, monocytes or macrophages most probably release mediators, 
which contribute to damage to the endothelium. An overactive host response may be 
important in the progression of the disease. In severe CCHF cases, high levels of cytokines 
most probably also contribute to the progression of the disease. In vitro studies have 
demonstrated that macrophages are susceptible to CCHFV and, as a result, increased levels 
of pro-inflammatory cytokines have been reported (Peyrefitte, Perret et al. 2010). A study of 
CCHF cases in Turkey found increased serum levels of TNF-α (Ergonul, Tuncbilek et al. 
2006). In other studies, high levels of interleukin-6 (IL-6), IL-10 and tumour necrosis factor-α 
(TNF-α) have been used as prognostic markers in CCHF patients (Papa, Bino et al. 2006, 
Saksida, Duh et al. 2010)  
Haemorrhage is usually observed when thrombocytopenia develops or the function of 
platelets is suppressed, but the bleeding is usually diffuse and haemorrhage is not alone the 
major factor responsible for the death of patients. However, viral dose seems to be correlated 
with a hyperactive host response. When this is combined with impaired immune response 
such as delayed production of type I interferons (IFNs) and absence of an antibody response, 
the disease can progress into more severe stages (Saksida, Duh et al. 2010). Endothelial 
damage and vascular collapse causing coagulation disorders and organ necrosis could be 
what leads to the shock syndrome and multi-organ failure observed in severe and fatal CCHF 
cases (Peters and Zaki 2002, Whitehouse 2004, Ergonul 2006).  
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ANIMAL MODELS 
Two animal models with a defective interferon response, IFNAR and STAT1 mice, in which 
CCHFV infection is lethal, have recently been developed (Bente, Alimonti et al. 2010, 
Bereczky, Lindegren et al. 2010). These animal models have been used to study the 
pathogenesis of the disease.The fact that these IFN knock-out mice are prone to fatal CCHFV 
infection indicates the importance of anti-viral mechanisms in the early innate response. The 
highest levels of CCHF vRNA are reported to occur mainly in the liver and spleen of IFNAR 
and STAT1 mice. (Zivcec, Safronetz et al. 2013)These organs are clearly affected, with 
observations of necrosis in the liver and massive lymphocyte depletion in the spleen, reflecting 
human disease patterns. Infected mice develop leukopenia, thrombocytopenia and elevated 
levels of liver enzymes. Furthermore, animal studies of CCHF have demonstrated increased 
levels of proinflammatory cytokines such as IL-6, IL-10 and TNF-α (Bente, Alimonti et al. 2010, 
Zivcec, Safronetz et al. 2013) 
 
PREVENTION, CONTROL AND TREATMENT 
Prevention and control 
In the patient care setting, standard barrier nursing (such as gloves, masks, face shields) and 
patient isolation are sufficient to prevent transmission of CCHF (Ftika and Maltezou 2013) 
(Ftika and Maltezou 2013).  
Differential diagnosis is important, since early non-specific symptoms of CCHF can mimic 
other infections, leading to misdiagnosis, increasing the risk of virus transmission and delaying 
appropriate treatment (Whitehouse 2004). 
There is a promising vaccine candidate (Buttigieg, Dowall et al. 2014) however in the absence 
of any commercial vaccine, prevention of disease relies on awareness regarding the link 
between the virus, vector and host and the potential risk of further viral spread to humans, 
including human-to-human transmission In a recent study examining risk factors for tick 
exposure, it was found that tick bites can be prevented by simple changes in behaviour, by 
understanding those at risk and by implementing barriers to prevent tick bites (Jones, Garman 
et al. 2002). It is important to implement preventive and protective behaviour such as proper 
clothing, with no exposure of naked skin, while the body and clothing should be inspected for 
ticks after being outdoors. Attached ticks should be removed without damaging the tick body, 
followed by cleaning the bite area with alcohol or soap and water (CDC, 2011). People in high 
risk occupations (slaughterhouse workers, veterinarians, shepherds) should avoid virus-
contaminated blood or tissue. For farmers, it is especially important to check for tick exposure 
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after handling livestock (Whitehouse 2004). Russian milkmaids recognised the possibility of 
infection with tick-borne diseases and therefore dressed from head to toe in white garments 
to allow them to check more easily for the presence of ticks (Dr Telford Work).  
Treatment  
General supportive therapy is often the best approach this includes monitoring patient status, 
administration of fresh frozen plasma to maintain levels of clotting factor, thrombocytes and 
blood transfusions following haemorrhage (Ergonul 2006). 
Administration of Ribavarin is the only medical treatment available and is an option during 
early infection. However, there is an ongoing debate regarding its antiviral effect (Tasdelen 
Fisgin, Ergonul et al. 2009). Ribavarin is an nucleoside analogue which has antiviral 
properties. The complete mechanism underlying this antiviral effect is not known, but it has 
been suggested to interfere with vRNA synthesis (Graci and Cameron 2006). The first 
clinical use of Ribavarin against CCHFV was documented in 1995, when three healthcare 
workers recovered after (Fisher-Hoch, Khan et al. 1995)  
As mentioned above, scientists have concluded that administration of Ribavarin is most 
effective in early infection, during viraemia. Later on, when the patient enters the haemorrhagic 
phase and viraemia has declined, a stage which is characterized by the release of pro-
inflammatory cytokines, sepsis and bleeding disorders, the approach should perhaps be to 
use drugs or compounds that address these issues (Ergonul 2008).  
Use of antibodies (immunoglobulin) from survivor donors may be of therapeutic importance 
(Hoogstraal 1979). Immunoglobulin has been used as treatment for CCHF patients in both 
Bulgaria and Turkey, but there is a lack of efficiency studies (control studies) in this field 
(Christova, Di Caro et al. 2009, Keshtkar-Jahromi, Kuhn et al. 2011, Kubar, Haciomeroglu et 
al. 2011) . 
. 
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HOST RESPONSE TO VIRAL INFECTION 
 
The host response to viral infections can be divided into different stages. The first line of 
defence includes physical barriers such as skin, low pH and fever that separates and protects 
the host from the outside world. If the mechanical barrier fails, e.g. the epithelial lining in 
humans and other mammals, the host still has a variety of defence mechanisms referred to 
as the immune system. It includes production of specialist cells and secretion of protective 
molecules/proteins which prevent microbial pathogens from evading the defences and 
establishing an infection in the host. 
The innate arm of the immune system acts quickly and in a blunt manner and therefore 
responds non-specifically to a large variety of pathogens. The early immune system is 
important since it helps to limit further spread and virus replication, thereby preventing and 
controlling the infection until it is eliminated or until the pathogen-specific adaptive arm of the 
immune system is established. This adaptive immune response is slower, specific and 
contributes to an immunological memory, which results in faster recognition and response in 
the event of a secondary infection with the same pathogen (Chaplin 2010). Important events 
early during infection include secretion of pro-inflammatory mediators, which are produced by 
most immune cells with the aim of detecting intruders such as pathogens, and activation of 
the adaptive immune response, which acts together with the innate arm. Chemokines recruit 
immune cells by chemotaxis, i.e. movement of the immune cells in response to stimuli. 
Cytokines such as interleukins (ILs) stimulate activation and recruitment of other cells, while 
IFNs can act in an autocrine or paracrine manner. The purpose of both is to induce expression 
of antiviral proteins, which helps to put cells in anti-viral mode, reduces cell permissiveness to 
virus infection and thereby slows down or inhibits virus multiplication. Besides their role as 
antiviral messengers, IFNs also buy the organism time to establish an adaptive immune 
response (Commins, Borish et al. 2010). IFNs have a wide array of biological functions 
including inhibition of cell proliferation, modulation of the immune response and regulation of 
apoptosis (Le Bon and Tough 2002). 
Another host anti-viral strategy is to commit cell suicide by activation of apoptotic pathways. 
Apoptosis or necrosis can help limit viral replication and the spread of infectious viral particles, 
and thereby protects the host from invading pathogens. In order for an invading virus to 
achieve successful viral replication and the production of progeny virus in order to establish 
infection, it has to be able to evade the apoptosis defence mechanism or use apoptosis as an 
mechanism which contributes to viral spread. 
While apoptosis is an programmed form of cell death, coordinated caspase activation. 
Necrosis involves acute cellular injury and is an uncontrolled form of cell death, often 
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considered to be a toxic process. Necrosis is characterized by cell swelling chromatin 
condensation and rupture and loss of cellular membrane integrity, which results in release of 
cellular contents into the surrounding tissue, thereby promoting inflammatory reactions  
Apoptosis is characterized by cell death without any leakage of cellular contents to 
extracellular space causing secondary damage. Characteristic cell changes such as cell 
shrinkage, chromatin condensation and cytoplasmic condensation are followed by plasma 
membrane blebbing and the formation of membrane-enclosed particles (containing cellular 
components) known as apoptotic bodies (Elmore 2007). These are further identified and 
engulfed (phagocytosed) by neighbouring cells. Through the formation of apoptotic bodies, 
the virus can disseminate without triggering any immune response, facilitating virus release. 
Since apoptotic cells do not release their cellular components, apoptosis is therefore 
considered to be a limited or non-inflammatory form of host cell suicide (Wickman, Julian et 
al. 2012). 
CASPASE- DEPENDENT APOPTOSIS 
The term apoptosis was initially used to describe a form of cell death associated with specific 
cellular morphological changes. Since then, molecular mechanisms, induced by both internal 
and external stimuli, have been characterized. Apoptosis is a cell-programmed suicide 
mechanism that results in controlled breakdown of cells into smaller apoptotic bodies. Key 
effector molecules in the apoptotic cascade include the B-cell lymphoma (Bcl)-2 superfamily 
and caspases. The Bcl-2 family has both pro-and anti-apoptotic members, which help to 
regulate apoptosis and prevent or induce mitochondrial changes. In inactive form these 
molecules are localized in the cytosol or present on the mitochondrial membrane 
(Zimmermann, Bonzon et al. 2001, Zimmermann and Pinkoski 2001). 
The cysteine aspartate-specific proteases (caspases) mediate the execution phase of 
programmed cell death. Caspases are among the most specific of proteases and require 
specific aspartic residues (Asp) for recognition and binding. Furthermore, different caspases 
have different specific recognition motifs which involve recognition of surrounding 
neighbouring amino acids (Thornberry 1998).  
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The caspases are categorized into different groups (Table 1): 
i) Mediators of inflammation: Caspase-1,-4 and -5 
ii) Effectors of apoptosis: Caspase-3,-7 and -2’ 
iii) Activators of apoptosis: Caspase-6,-8,-9 and -10 
 
Table 1. Composition of the three main groups of caspases: The inflammatory caspases mediate cytokine 
maturation, while the apoptotic caspases are either effectors of cell death or upstream activators of the cell death 
process 
 
 
There are two major pathways for initiating apoptosis: the extrinsic pathway, which responds 
to external stimuli, and the intrinsic pathway (mitochondria-dependent pathway) causing 
alteration of the mitochondrial membrane function. Both pathways rely on activation of 
caspases. Activation of execution caspases is controlled by upstream initiator caspases, which 
are responsible for the apoptotic signalling cascade that finally ends with cell death.  
Groups of caspases Sequence Function
Mediators of 
inflammation
Caspase-1 W  E  H  D Activate pro-
inflammatory cytokines
Caspase-4 W or L  E  H  D
Caspase-5 W or L  E  H  D
Effectors of apoptosis Function primarly in 
apoptosis
Caspase-3 D  E  V  D Cleavage of cellular
structural proteins
Caspase-7 D E  V  D
Caspase-2 D  E  H  D
Activators/Initiators of 
apoptosis
Function primarly in 
apoptosis
Caspase-6 V  E  H  D
Caspase-8 L  E  T  D
Caspase-9 L  E  H  D
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The extrinsic pathway 
Cytokines such as Fas ligand (FasL) and TNF-α bind to death receptors, which initiate the 
extrinsic pathway, activation of initiator caspase-8 and further downstream caspase activation, 
or via interconnection with the intrinsic pathway by activation of BH3-interacting domain death 
agonist (Bid). Bid is a proapototic member of the Bcl-2 superfamily and is cleaved and 
activated by caspases to form a truncated fragment, which then translocates to the 
mitochondria (Thornberry 1998, Zimmermann, Bonzon et al. 2001) (Figure 5). 
 
The intrinsic pathway 
Mitochondria have several important functions, such as production of cellular energy (ATP), 
regulation of cellular metabolism and several other functions. The intrinsic or mitochondria 
pathway is associated with changes in the mitochondrial membrane, leading to release of 
mitochondria proteins, which serve as inducer molecules for caspase activation. Release of 
mitochondrial proteins can be caused by intracellular stress and by host pro-apoptotic 
proteins, induced by the extrinsic pathway, that target the mitochondria, causing loss of 
mitochondria integrity such as swelling, formation of membrane pores and increased 
permeability of the mitochondrial membrane. There is most probably cross-talk between the 
extrinsic and intrinsic pathways, for example by activation of Bid-tBid. After translocation to 
the mitochondria, tBID interacts with cellular pro-apototic proteins which cause these changes 
in the mitochondrial membrane. Changes in mitochondrial permeability are regulated by anti- 
and pro-apoptotic proteins such as the Bcl-2 superfamily. Proteins encoded by this family can 
either promote apoptosis (Bax, Bak) or inhibit apoptosis (Bcl-2, Bcl-xL), by direct action on the 
mitochondrial outer membrane, allowing leakage of apoptotic proteins such as cytochrome-c. 
Once cytochrome-c is released, it binds to apoptotic protease activating factor-1 (Apaf-1), 
which forms the apoptosome and further activates caspase-9, which in turn results in 
downstream executor caspase activation (Thornberry 1998, Zimmermann, Bonzon et al. 
2001) (Figure 5).  
 
Execution phase 
The final step of apoptosis ends at the same point for both the extrinsic and intrinsic pathways, 
namely the execution phase. Execution caspases include caspase-3, caspase-6 and 
caspase-7, with caspase-3 considered to be the most important. It is activated by any of the 
initiator caspases (caspase-8, caspase-9, or caspase-10) (Sakahira, Enari et al. 1998). 
Execution or downstream caspases further cleave various cellular substrates such as poly 
(ADP-ribose) polymerase (PARP), which is involved in DNA repair and is an indicator of cells 
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undergoing apoptosis, since caspase cleavage of PARP leads to inhibition of the PARP 
function (repairing ssDNA nicks) (Thornberry 1998, Thornberry and Lazebnik 1998). 
 
 
 
Figure 5. Schematic representation of the main molecular pathways leading to apoptosis (Favaloro, Allocati et al. 
2012). 
 
Removal of apoptotic cells  
The last step during the apoptotic process is the removal or phagocytosis of apoptotic bodies 
by neighbouring cells. Phagocytic molecules such as phosphatidyl serine are transferred from 
the cytosolic inward-facing surface of the plasma membrane to the extracellular surface or 
outer-facing layer of apoptotic cells. These molecules are markers or recognition signals and 
allow uptake, “eat me-find me signals”, that result in phagocytosis of dying cells with limited 
damage to surrounding tissue and thereby minimal immune response (Fadok, de Cathelineau 
et al. 2001, Wickman, Julian et al. 2012)  
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Modulation of host antiviral response 
Viruses have different strategies to interfere with cell death pathways during infection to secure 
efficient progeny viral production by expressing viral proteins (encoding gene products) or 
down-/up-regulating cellular pro- and anti-apoptotic proteins, which interfere with apoptotic 
signalling pathways.  
Apoptosis and/or modulation of apoptopic signalling pathways has been observed for several 
members of the Bunyaviridae, such as Rift Valley fever virus (RVFV), Bunyamwera virus 
(BUNV), La Crosse virus (LACV), Oropuche virus (OROV) and Hantaan virus (HTNV) (Won, 
Ikegami et al. 2007, Kohl, Clayton et al. 2003, Pekosz, Phillips et al. 1996, Colon-Ramos, 
Irusta et al. 2003, Acrani, Gomes et al. 2010, Gupta, Braun et al. 2013, Ontiveros, Li et al. 
2010). 
 
ANTI-VIRAL STATE INDUCED BY INTEFERONS TYPE I 
 
Pattern recognition receptors 
Detection of microorganisms in the host is facilitated by a set of intracellular and 
transmembrane proteins termed pattern recognition receptors (PRR), which recognize 
structures of pathogens either through pathogen-associated molecular patterns (PAMPs) 
displayed on the surface or by being a part of their genome. Since many microorganisms 
express the same PAMPs, the host can detect a large variety of pathogens via PRR. Both 
extra and intracellular recognition by PRR lead to a signalling cascade, which results in 
expression and secretion of IFNs and/or cytokines that activate, or mediate the activation of, 
the adaptive immune response (Takeuchi and Akira 2010). 
Extracellular and endosomal recognition  
One example of the PRR are the toll-like receptors (TLRs). These transmembrane proteins 
are either located on the cellular membrane and recognize and bind to microorganism 
structures such as lipopolysaccharides (LPS) and flagellin, or are located on the endosomes 
and bind to genetic entities such as the DNA/RNA of micro-organisms. For example, TLR-3 
detects double-stranded RNA (dsRNA), TLR-7 and TLR-8 recognize single-stranded RNA 
(ssRNA) virus genomes and TLR-9 recognizes DNA viruses. TLR-3 is found in the plasma 
membrane as well intracellularly in the endosomes and TLR-7 and TLR-9 are located in the 
endosomes of cells (Akira and Takeda 2004).  
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Intracellular recognition 
An example of PRR, that responsible for intracellular recognition of pathogens, is created by 
the retionic acid-inducible gene-1 (RIG-I) and melanoma differentiation antigen-5 (MDA-5). 
RIG-I and MDA-5 are the two main intracellular receptors for binding viral RNA upon activation, 
triggering a signalling chain that activates IFN-β gene expression (Takeuchi and Akira 2007, 
Yoneyama, Onomoto et al. 2008). Although RIG-I and MDA-5 have a similar protein structure 
and share a similar signalling pathway, it has been demonstrated these two RNA helicases 
discriminate in sensing different viral patterns, suggesting a degree of specificity. RIG-I binds 
to short dsRNA molecules, while MDA-5 recognizes and binds to long dsRNA structures (Kato, 
Takeuchi et al. 2006, Loo, Fornek et al. 2008). However, this division of mode may be 
oversimplified, since recent studies have found that RIG-I has the ability to bind to ssRNA with 
triphosphate at the 5´end of the genome (Hornung, Ellegast et al. 2006, Pichlmair, Schulz et 
al. 2006) 
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Inteferon (IFN) induction 
Interaction of antigen to PRR starts a signalling chain which results in activation of transcription 
factors, for example by nuclear factor κB (NF-κB) or IFN regulatory factor-3 (IRF-3). Both NF-
κB and IRF-3 are normally held in the cytoplasm in inactive state. For its activation, NF-κB 
requires degradation of inhibitory proteins, while IRF-3 is activated by phosphorylation of 
different residues. This allows translocation into the nucleus, where both initiate IFN-β gene 
expression and secretion of IFN-β (Figure 6). The first wave of IFNs triggers expression of 
IRF-7, which initiates synthesis of several subtypes of IFN-α. Although there are different types 
of IFNs, all share the same downstream signalling pathway, the Janus 
kinase/signal transducers and activators of transcription (JAK-STAT) signalling pathway. 
Upon binding of IFNs to type I IFN receptor (IFNAR), Janus kinases (JAKs) are activated to 
phosphorylate, and thereby activate, downstream substrates such as STAT-1 and 2, which 
together with IRF-9 form a complex called IFN-stimulated gene factor 3 (ISGF-3). It in turn 
induces transcription of several IFN-stimulated genes and a second wave of IFN-α/β 
expression (Smith, Lombardi et al. 2005, Weber and Mirazimi 2008).  
 
 
Figure 6. Type I interferon (IFN) induction, signalling and release (Weber and Mirazimi 2008).  
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Inteferon stimulated genes (ISG) products 
Synthesis of IFNs is considered to be efficient and rapid host response and is important for 
clearance of virus infection. Secreted IFNs can stimulate neighbouring cells to express 
antiviral proteins. IFNs can contribute to induction of an antiviral state in host cells and thereby 
help the host to limit viral replication and further viral spread (Haller, Kochs et al. 2006). A few 
proteins have been characterized and are reported to be induced by a set of genes with 
antiviral effect, referred to as interferon-stimulated genes (ISGs) (Balachandran, Kim et al. 
1998).  
One of the ISGs up-regulated following IFN stimulation is IRF-7, which in turn initiates IFN-α 
genes and thereby production of a full range of IFNs. Other IFN-induced antiviral proteins are 
protein kinase R (PKR), Mx GTPases such as human MxA and ISG15-ubiquitin-like 
molecules, the 2´-5´oligoadenylate synthetases (OAS) and ISG20. 
The Mx proteins are present in a number of species, including humans. The human MxA 
interferes with viral replication soon after entry to the host cell upon sensing dsRNA, and can 
interact with viral nucleocapsid proteins of members of the Bunyaviridae. In this manner they 
restrict their cellular location, preventing nucleocapsids from taking part in (their normal 
function of) viral RNA synthesis and thereby limiting viral replication (Zurcher, Pavlovic et al. 
1992, Kochs, Janzen et al. 2002, Andersson, Bladh et al. 2004, Haller and Kochs 2011).  
PKR is activated by viral dsRNA and 5´triphosphate group ssRNA and blocks viral mRNA 
translation and general host protein synthesis by phosphorylation of the eukaryotic initiation 
factor 2α (eIF2α) by PKR (Zhu, Romano et al. 1997, Sadler and Williams 2008).   
Cellular exonucleases are important for the protection against pathogens. Activation of 
RNaseL contributes to degradation of viral RNA and thereby prevents virus replication and 
protein synthesis. Another cellular exonuclease, ISG20, seems to be a part of this antiviral 
effect by degrading ssRNA. Besides the direct antiviral effects, PKR also mediates apoptosis 
and regulates cell proliferation (Gil and Esteban 2000)  
Viruses are intracellular organisms, meaning that they can only reproduce within a host and 
need to use host cellular replication machinery for multiplication and to ensure transmission 
and spread to new hosts. For this to be achieved in the presence of early, innate, antiviral 
defence mechanisms, most viruses have evolved strategies to interfere with the IFN response. 
The presence of virus antagonists designed to interfere with different signalling pathways, 
such as the IFN response, enables viruses to replicate and secure progeny virus production 
and thus continue the course of infection.  
Viral encoded IFN antagonists can target specific components of the IFN system by 
suppressing, delaying or inhibiting induction of IFN signalling or inhibiting the effects of antiviral 
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protein induced by ISGs. In addition, some viruses block or shut-off general protein synthesis 
in order to ensure their survival.    
One role of non-structural (NSs) proteins for both phleboviruses and orthobunyaviruses is to 
act as inhibitors of the host antiviral response. Rift Valley fever virus NSs target the antiviral 
response by blocking IFN production early during the viral replication cycle by inhibiting IFN-β 
gene transcription and interfering with or down-regulating the antiviral protein PKR (Bouloy, 
Janzen et al. 2001, Billecocq, Spiegel et al. 2004). 
The NSs of both BUNV and LACV block the IFN response on host transcriptional level by 
targeting RNA polymerase II (Thomas, Blakqori et al. 2004, Verbruggen, Ruf et al. 2011)  
Another strategy to counteract the host early immune response and IFN signalling pathways 
is to avoid intracellular RIG-I recognition, a survival tactic demonstrated for members of the 
hantaviruses and nairoviruses. The major determinant of RIG-I activation is 5´triphosphate, a 
structure that is not normally present in cellular proteins in viral RNA and that is not activated 
by the CCHFV genome, which instead generates 5´monophosphate (Habjan, Andersson et 
al. 2008, Weber, Gawanbacht et al. 2013). 
Viruses use different strategies to interfere with the IRF-3 pathway. The Ebola virus and 
hepatitis C virus inhibit IRF-3 phosphorylation (Basler, Mikulasova et al. 2003) (Foy, Li et al. 
2003) CCHFV also inhibits IRF-3 activation early during the replication cycle, but further 
research is needed to characterize the mechanism and determine whether this delay reflects 
the avoidance of RIG-I recognition early during the virus replication cycle (Andersson, Karlberg 
et al. 2008). 
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1 AIMS 
 
          To investigate 
 
 
- Whether CCHFV interferes with the early host immune response during infection 
(Paper I) 
 
- The role of conserved DEVD motif and investigate the outcome of caspase activation 
and cleavage of CCHFV nucelocapsid protein in different human cell types during 
infection (Paper II) 
 
 
- The possible role of caspase-3 cleavage sites by using a structure of CCHFV  
nucelocapsid protein (Paper III) 
 
 
- How the CCHFV replication cycle interacts with apoptotic pathways (Paper IV) 
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RESULTS  
Paper I 
CCHFV delays induction of Type I interferon in infected cells 
To address whether replication of CCHFV interferes with the IFN response, we established a 
bioassay based on a recombinant, IFN-sensitive, New Castle Disease virus (NDV) expressing 
green fluorescent protein (GFP). In this bioassay, no biologically active type I IFN was found 
in supernatant harvested 24 hours post infection. However, at 48 hours post infection, 
substantial amounts of IFN were found in the media (Fig. 1). RT-PCR analysis of the infected 
cells supported the findings from the bioassay (Fig.1).  
In order to investigate whether CCHFV had the ability to interfere with IFN responses, we 
compared the expression of ISG56 following CCHFV infection to UV-irradiated virus infection. 
ISG56 is a highly sensitive IFN-stimulated gene and a useful marker for early immune 
responses. A549 and Huh-7 cells were infected with native and UV-treated virus and analysed 
with RT-PCR at different times post infection. In both cell types, ISG56 mRNA was detected 
at 3 hours post infection in cells infected with UV-treated virus. However, in cells infected with 
native CCHFV, ISG56 mRNA was not detected until 24 hours post infection (Fig. 2) 
CCHFV delays activation of IRF3 
In addition, we investigated the ability of CCHFV to interfere with IRF-3 nuclear translocation. 
In an immunofluorescence analysis, we found that IRF-3 was translocated to the nucleus after 
only 3 hours in cells infected with UV-irradiated CCHFV. In contrast, in cells infected with 
CCHFV, nuclear translocation of IRF-3 was not observed until 24 hours post infection (Fig. 3) 
Paper II 
CCHFV N has a specific cleavage motif for caspase-3 
Examination of the primary structure of CCHFV N demonstrated a potential motif for caspase 
cleavage (DEVD) at position 266-269 of the nucleocapsid (N) protein. Comparison with 
available sequences of S segment of CCHFV in the gene bank revealed that this motif was 
conserved in all available strains (Fig. 1). To determine whether this motif in N is cleaved 
during apoptosis, recombinant SFV was produced in order to express CCHFV N. BHK cells 
were infected with recombinant SFV (moi=1) and cells were harvested at different times post-
infection. As shown in Fig. 2, in contrast to mock-infected cells, the cleavage form of PARP 
was present at 24 hours and was more pronounced in cells collected at 48 hours post infection, 
which indicates activation of caspase-3. In addition to the expected full-length protein of 56 
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kDa, several fragments of NP were detected, including a smaller 30 kDa fragment of N at 48 
hours post infection (Fig. 2).  
In order to confirm that the DEVD motif (Fig. 1 ) is a subject for caspase cleavage, we created 
two mutants of CCHFV N, lacking the predicted cleavage site of N. BHK cells were infected 
with rSFV-expressing mutants and the native form of N, cells were harvested and the 
expression pattern of N was analysed (Fig. 2). 
Caspase activation at late times post infection 
To determine whether the cleavage of N occurs during CCHFV infection, SW13, HUVEC and 
A549 cells were infected with CCHFV (moi=1). Supernatant was collected at different times 
post infection and analysed. As shown in Fig. 3, we were able to demonstrate the appearance 
of a cleaved 30 kDa N product in the culture supernatant at 48 hours post infection. However, 
this fragment was more strongly manifested at 72 hours post infection.  
To determine whether CCHFV infection induces apoptosis, we performed a TUNEL assay 
(DNA strand breaks). SW13 cells were mock-infected or infected with CCHFV (moi=1). At 
72 hours post infection, cells were collected and analysed by TUNEL assay (Fig. 4). The 
results demonstrated that CCHFV infection induced significantly more TUNEL-positive cells 
compared with mock-infected cells.  
To study cleavage of N in more detail, SW13 cells were mock-infected or infected by CCHFV 
(moi=1). Cells were harvested and analysed for detection of PARP and caspase-3. As shown 
in Fig. 5, we observed cleavage of PARP and N at 72 hours post-infection. We were also able 
to demonstrate the presence of activated caspase-3 in infected cells at the same time (Fig. 5).  
In order to confirm that the cleavage process of N is caspase-3-dependent, SW13 cells were 
mock-infected or infected with CCHFV (moi=1) and after 1 hour cells were mock-treated or 
treated with caspase-3 inhibitors at different concentrations. Cells were harvested at 48 and 
72 hours post infection. As shown in Fig. 6, we were able to clearly demonstrate that caspase-
3 inhibitor completely inhibited cleavage of N. To confirm these results, we infected MCF-7 
cells, which do not express caspase-3, with CCHFV (moi=1). Cells were harvested at different 
times post infection and analysed. We did not find the 30 KDa fragment of N, but we were able 
to detect cleavage of PARP (Fig. 6). 
To study whether caspase-3 induced apoptosis has an inhibitory effect on yield of progeny 
virus, SW13 cells were infected with CCHFV (moi=1). These infected cells were then mock-
treated or treated with caspase Inhibitors. Supernatant was collected at 24 and 48 hours post 
infection and the amount of infectious virus particles determined (Fig. 7). 
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Paper III  
CCHFV RNA segments are encapsidated by the nucleocapsid protein (CCHFV N) to form the 
ribonucleoprotein complex 
In analyses of the crystal structures of the CCHFV N, we found two distinct forms, an 
oligomeric form comprised of double antiparallel super helices and a monomeric form. We 
also demonstrated that the conserved caspase-3 cleavage site is located at the top, α12-α13 
loop, of the stalk domain. This domain is directly involved in the head-to-tail interaction of the 
CCHFV N molecules and leads to the formation of the superhelical oligomeric form of CCHFV 
N (Fig. 2). Modelling studies on the interaction with caspase-3 at the caspase cleavage site of 
CCHFV N in this superhelical form revealed that the head-to-tail interaction of CCHFV N 
molecules obscures the caspase-3 cleavage site and thus would prevent binding and 
subsequent cleavage by caspase-3 (Fig. 2).  
Incubation with primer-length ssRNA results in conformational change of oligomeric CCHFV 
N and release of monomeric CCHFV N 
When CCHFV N was crystallised in the presence of primer-length ssRNAs (12-16 base long 
ssRNAs), the structure crystallised under different conditions and only one CCHFV N molecule 
was observed in the asymmetrical unit (Table 1).  
Superposition of the monomeric CCHFV N structure on the molecules from the superhelical 
structure revealed that a conformational change had indeed occurred upon incubation with 
primer-length ssRNAs. Rotation of the stalk domain led to destruction of the superhelical 
oligomer and, as a result, release of monomeric N. This release of the free, monomeric N is 
likely to result in the exposure of the caspase-3 cleavage site situated at the loop region at the 
tip of the stalk domain to host cell caspase-3. To confirm this hypothesis, we incubated purified 
recombinant N with or without ssRNA followed by treatment with caspase-3. Cleavage of 
CCHFV N by caspase-3 was observed only in the presence of primer-length ssRNA (Fig. 4).  
Mutation of the CCHFV N caspase-3 cleavage site enhances viral RNA synthesis 
In order to determine the effect of the caspase-3 cleavage site of CCHFV N on viral RNA 
synthesis activity, we performed minireplicon assays using wild-type CCHFV N or a CCHFV 
N mutant with the conserved cleavage site mutated to evade caspase-3 cleavage. The results 
demonstrated that on abolishing the caspase-3 cleavage site of CCHFV N, RNA synthesis by 
CCHFV polymerase was enhanced (Fig. 5). We also attempted to detect cleaved wild-type 
CCHFV N fragments by Western blotting, but no cleavage products were detected, 
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presumably because concentrations of cleaved N from the minireplicon assay were below 
detectable levels.  
Paper IV 
CCHFV replication suppresses caspase activation both upstream and on executor 
caspase level  
Mock-infected and CCHFV-infected SW13 cells (moi 1 at 24 h post infection) were treated 
with different concentrations of STS, a relatively non-selective protein kinase inhibitor, which 
is often used as a general method for inducing apoptosis. At 5 hours post treatment, cells were 
harvested and analysed by Western blot. It was found that cleavage of PARP was clearly 
suppressed in the CCHFV-infected cells compared with the mock-infected cells, in the 4 uM 
STS treatment (Fig. 1).  
To investigate whether caspase-3 activation is regulated during CCHFV infection, SW13 cells 
were infected and treated as described above (with 4uM STS) and analysed for the presence 
of caspase-3 cleavage. It was found that the activation of caspase-3 in the STS treated 
CCHFV infected cells was significantly reduced compared with STS treated mock-infected 
cells (Fig. 2).  
To further characterise the interaction of CCHFV replication and the apoptosis pathway, we 
analysed these samples for STS-induced cleavage of caspase-9. The results showed that 
cleavage of caspase-9 was also suppressed during the early phase of the CCHFV replication 
cycle in STS-treated infected cells, in contrast to mock-infected cells (Fig. 2).  
CCHFV infection interplays or interferes with apoptotic molecules-pathways 
Mock-infected and CCHFV-infected cells (at 24 h post infection) were mock-treated or treated 
with STS. Attached and detached cells were harvested at 5 h post treatment, and the cytosol 
and mitochondria fractions were collected separately and analysed for estimated release of 
cytochrome-c by Western blot. It was found that release of cytochrome-c into the cytosol was 
decreased in infected cells compared with mock-infected cells, for both attached and detached 
cells (Fig.3). 
To investigate whether the CCHFV N protein is involved or contributes to regulatory properties, 
we established an in vitro model system The SW13 cells were transfected, with a plasmid 
coding for ORF N (myc-N), different concentrations, and a plasmid coding for Bax (flag-Bax). 
Induction of apoptosis in the presence and absence of CCHFV N was then analysed by 
measuring the activation of caspase-3. Overexpression of Bax in SW13 cells induced high 
level of caspase-3 activation and cleavage of endogenous PARP, when compared with mock 
transfected cells. Caspase-3 activity decreased with increasing concentration of N (Fig. 4).  
 29 
 
Potential mechanisms contributing to induction of apoptotic pathways 
SW13 were mock-infected or CCHFV-infected (moi 1). At 24 and 48 h post infection, cells 
were harvested and analysed for activation and cleavage of Bid (truncated Bid, tBid). The 
results clearly demonstrated that CCHFV infection at late post infection led to cleavage of Bid 
to tBid in cells (Fig. 5).  
Supernatant from mock-infected and CCHFV-infected cells at late times post infection was 
UV-inactivated and transferred to seeded new SW13 cells. At 24 h, cells were harvested and 
analysed by Western blot for presence of PARP. The results showed that activation and 
cleavage of PARP was induced in cells that had been treated with supernatant from cells at 
late post infection (Fig. 6). This is most likely caused by pro-inflammatory mediators released 
into the medium as a cellular protective response to infection. This suggests in turn that 
caspase activation is triggered by external stimuli as a secondary effect. Analysis of 
supernatants of SW13 cells harvested at different times post infection demonstrated that 
CCHFV-infected cells secreted TNF-α at late post infection.  
In order to characterise the process in more detail, supernatant collected at 48 h post infection 
from infected cells was mock-treated or treated with neutralising TNF-α antibodies (5 ug/mL) 
for 1 h at 37oC and transferred to seeded SW13. At 24 h post treatment, detached cells were 
harvested and analysed with Western blot. The analysis showed that antibodies against TNF-
α suppressed cleavage of PARP (Fig. 6), indicating that TNF-α secreted from infected cells is 
a contributor to induction of the extrinsic apoptotic pathway during the late phase of infection. 
However, the neutralisation was not complete, most probably because we could not neutralise 
all TNF-α or because other molecules are also involved in triggering the extrinsic pathway. 
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DISCUSSION 
CCHFV N has a conserved caspase-3 cleavage site 
CCHF disease in humans shows a spectrum of severity, from mild to acute. The specific 
underlying mechanism of both the clinical and molecular pathogenesis is still unknown for 
CCHF and other VHF. Knowledge regarding CCHFV-host cell interaction is also limited 
therefore the work presented in this thesis focused on understanding how CCHFV replication 
in host cells interplays with apoptosis and uncovering the mechanism behind this process. 
Paper II demonstrated a potential motif for caspase-3 cleavage (DEVD) at positions 266–
269 of the nucleocapsid protein. Comparison with available sequences of the S segment of 
CCHFV in GenBankTM revealed that this motif was conserved in all available strains. By 
studying the crystal structures, paper III, of CCHFV N, we observed two different 
conformations of N namely, a double superhelical oligomeric form and a monomeric form. 
Monomeric N protein is presented as a large globular domain with a protruding stalk domain, 
where the DEVD site is found in the middle section of N which forms the extended arm. In 
this state the caspase-3 cleavage site is placed on the most accessible position on the entire 
molecule and not protected for caspase cleavage. The globular domain has been 
demonstrated to be important for viral RNA binding. In contrast to the monomeric form, the 
superhelical oligomer of N the DEVD site is obscured and not available for binding to 
caspase-3. N protein free as a monomer might be one way for the polymerase to get access 
to vRNA for transcription and replication. 
We, furthermore, demonstrated that the polymeric N undergo a conformational change upon 
incubation with primer-length ssRNAs (Paper III). The major change involved in this process 
was rotation of the stalk domain, with head-to-tail interaction allowing release of free 
monomeric N. We hypothesised that release of this free monomeric N would result in 
exposure of the caspase-3 cleavage site situated at the tip of the stalk domain to host cell 
caspase-3. To confirm this hypothesis, we incubated purified recombinant N with or without 
ssRNA followed by treatment with caspase-3. Cleavage of CCHFV N was observed only in 
the presence of primer-length ssRNA. This confirms our observations in the crystal structure 
studies, whereby the presence of primer-length ssRNA would cause exposure of the 
caspase-3 cleavage site of CCHFV N by inducing a conformational change in the protein.  
It is interesting to speculate how the interaction between N and these short RNA (primer-
length) mimics a step of the CCHFV life cycle in mammalian cells. One might suggest that 
interaction of primers to RNP, may induce the early step of replication of CCHFV in cytosol. 
Bunyavirus transcription are suggested to rely on primers generated from capped host-cell 
mRNAs (Carter, Surtees et al. 2012). Therefore, it is also possible that primer-length RNA 
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represents mRNA caps to initiate transcription-mRNA synthesis. Our results suggest the 
interaction between N and RNA regulates the conformation of N and determines if the DEVD 
motif is exposed for caspase cleavage. 
By developing several in vitro model system based on different human cell lines, we found 
that N underwent cleavage, forming two cleavage products in the late CCHFV replication 
cycle. Using caspase-3 inhibitor and MCF-7 cells, deficient in caspase-3, we found that 
cleavage of N to a 30-kDa fragment is due to caspase-3 cleavage. Furthermore, we found 
that caspase inhibitors increased the yield of progeny virus. These findings suggest that 
caspase cleavage of N does not favour the production of new infectious viral particles. 
Therefore, we suggest that this event is induced by the host cell as a protective response to 
CCHFV infection. Viruses have different strategies to interfere or interplay with the host 
immune response. For example, transmissible gastroenteritis coronavirus (TGEV) infection 
results in caspase activation and the TGEV nucleoprotein (N) undergoes cleavage in parallel 
with induced apoptosis. It has been demonstrated that the N protein is a substrate for both 
caspase-6 and -7 and it is suggested that this could be a general mechanism by which 
infected cells eliminate coronaviruses, since only the full-length N protein is incorporated 
into the coronavirus particles. However, production of virions might depend on the ability of 
the virus to replicate rapidly, since the cleavage process appeared to have a limited influence 
on viral yields (Eleouet, Slee et al. 2000).  
On the other hand, the cleavage of N by caspases appears to be important for the life cycle 
of some viruses. Influenza A N protein also has caspase cleavage sites, which have been 
shown to be important for the viral life cycle. Studies using a reverse genetic system have 
demonstrated that mutations of the N-and C-terminal cleavage motif never lead to rescue of 
recombinant virus, which suggests that this alteration leads to no surviving viral particles. 
(Zhirnov, Konakova et al. 1999, Zhirnov and Syrtzev 2009). 
To further study the role of the DEVD site on N, we generated CCHFV N with a mutation at 
the DEVD site. By using a minireplicon assay (Paper III), we demonstrated that RNA 
synthesis activity of the polymerase is higher in DEVD-mutated N compared with wild-type 
N. This is most probably, due to that the mutated form of N, cannot undergo degradation 
and thereby there are more full-length protein available for replication process. The results 
of the minireplicon assay were consistent with our previous findings that titres of CCHFV 
decreased, when N was targeted by caspase-3 cleavage (Paper II). Hence, it is possible 
that cleavage of N is a way for the host response to slow down virus multiplication and 
thereby gain time to mount an effective anti-viral response, or it may just accidently happen 
and have no real purpose. Alternatively, it is possible that the concentration of full length N 
is important for transition from transcription to replication which further suggests that it is a 
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way for the virus to down regulate its own expression in order to evade host response 
(Flusin, Vigne et al. 2011). 
Since our results suggest that the DEVD motif is not beneficial for CCHFV replication, one 
may expect that a fast mutating RNA virus would eliminate the motif easily if there is no 
fitness cost. However, as the DEVD is conserved across different strains of CCHFV, we 
hypothesize that the cleavage of N or the DEVD motif itself may play a role in other aspects 
of CCHFV infection. Firstly, the cleavage products may play a role in the pathogenesis of 
the CCHF disease. Secondly, our crystallography studies show that the DEVD motif is 
directly involved in the head-to-tail interaction of N in the oligomeric form and thus it may be 
involved in controlling the dynamics of conformation changes between the oligomeric and 
monomer forms of N. This dynamic is critical because the oligomeric and monomeric forms 
have different importance at different stages of the virus life-cycle. 
Last but not least, we should highlight that CCHFV is a tick borne virus, thereby it is most 
possible to believe that there are other functions related to this cleavage site in replication 
cycle in tick cells. Humans are dead end host (accidently become infected) and replication 
in mammals is transient, while ticks remain infected throughout their several-year lifetimes, 
why it is reasonable that ticks has developed strategies to control infection and perhaps 
CCHFV during evolution has also developed strategies to suppress or even take advantage 
of host-tick defense and can live with the ticks in symbiosis.  
 
CCHFV delays/inhibits intrinsic apoptotic pathways 
By performing several different analyses on infected SW13 cells, we demonstrated that 
caspase-dependent apoptotic pathways are induced at late CCHFV infection (Paper II). 
However, since caspase activation does not favour CCHFV progeny viral production, we 
examined what happens early in the viral replication cycle. We found that apoptotic signalling 
pathways are regulated by CCHFV early during CCHFV infection (Paper IV). By challenging 
CCHFV-infected cells at 24 h post infection with STS, which is known to induce apoptosis, we 
were able to show that activation both upstream and at executor caspase level (caspase-9 
and caspase-3) was suppressed by CCHFV replication.  
To determine what causes the regulation or suppression of apoptotic pathways, we 
investigated whether changes in mitochondria membrane integrity could be involved in 
triggering apoptosis by release of pro-apoptotic proteins such as cytochrome-c from the inter-
membrane space into the cytosol (Zimmermann, Bonzon et al. 2001). The cytochrome-c and 
Apaf-1 released form a complex known as the apoptosome, leading to caspase-9 activation, 
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which further activates downstream effector caspases (Zimmermann, Bonzon et al. 2001). In 
Paper IV, we demonstrated that secretion of cytochrome-c from the mitochondria into the 
cytosol was decreased in STS-treated CCHFV-infected cells, but not in control cells. This 
indicates that the release of mitochondria proteins is regulated and caspase activation 
downstream of mitochondria level, including caspase-3, is suppressed or delayed during the 
early phase of CCHFV infection.  
It has previously been demonstrated that hepatitis C virus (HCV) encodes proteins with anti-
apoptotic activity which interfere with apoptosis signalling pathways by different mechanisms. 
HCV NS2 interferes with caspase-dependent induced apoptosis by counteracting 
cytochrome-c release from mitochondria, which contributes to viral persistence by interfering 
with host cell defence (Erdtmann, Franck et al. 2003). In the mitochondrial pathway, pro-
apoptotic members of the BCL-2 super family are associated with the mitochondria and 
release of cytochrome-c. Bax is one of the key pro-apoptotic (BCL-2 member) molecules, an 
inactive monomer, and is normally found in the cytosol or loosely bound to the mitochondria 
membrane. Upon activation by apoptotic stimuli, Bax changes confirmation and forms 
oligomers, which are then integrated by formation of membrane pores that facilitate release of 
mitochondrial proteins such as cytochrome-c, which leads to downstream caspase activation 
(Wolter, Hsu et al. 1997, Antonsson, Montessuit et al. 2000).  
By using a recombinant expression system, we showed that the over-expression of CCHFV 
N could inhibit Bax-induced apoptosis (Paper IV). These results indicate that the CCHFV N 
has the ability to protect against apoptosis by acting at the level of Bax or downstream of it. 
Hence N could be one of the major factors controlling caspase pathways and cell death in the 
early phase of infection. 
It has recently been demonstrated that rubella virus (RV) capsid protein interferes with import 
of Bax into mitochondria and thereby prevents mitochondria membrane permeabilisation and 
promotes cell survival (Ilkow, Weckbecker et al. 2010). It has also been reported that Hantaan 
virus (HTNV) nucleocapsid protein modulates apoptosis pathways through NF-ƙp (Ontiveros, 
Li et al. 2010).  
As discussed above, this thesis provides evidence that at early post infection, CCHFV infection 
is able to inhibit caspase-3 activation through regulation of cytochrome-c release by 
interplaying or interfering with Bax. External stimuli through the death receptor pathway might 
initially induce caspase activation, triggered by the viral infection, and often result in crosstalk 
between the extrinsic and intrinsic cell death pathways through the pro-apoptotic member Bid, 
thereby facilitating induction of the mitochondrial pathway (Eleouet, Chilmonczyk et al. 1998, 
Perez and White 2000). Transmissible gastroenteritis virus infection induces both the Fas L 
and mitochondria pathways through interconnection with Bid (Ding, Xu et al. 2012). 
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Role of innate immune response and inflammatory factors in CCHFV-induced apoptosis 
In Paper IV, we demonstrated that Bid is active at late post infection and also that supernatant 
of CCHFV-infected cells contains pro-inflammatory factors, which can induce extrinsic 
apoptosis. Taken together, these findings indicate that CCHFV at late post infection most 
probably induces apoptosis through induction of pro-inflammatory factors, which in turn 
activates the extrinsic apoptotic pathway. This assumption is in line with the finding that UV-
inactivated supernatant collected from CCHFV-infected cells at late post infection can induce 
cleavage of PARP in non-infected cells as early as 24 h post treatment. Since all the 
supernatants collected were UV-inactivated before being transferred to the fresh cells, 
apoptosis could not have been induced by virus replication. Induction of apoptotic pathways 
is most likely caused by pro-inflammatory mediators released into the medium as a cellular 
protective response to infection. This suggests in turn that caspase activation is triggered by 
external stimuli as a secondary effect after virus replication.  
This thesis also demonstrated that neutralising TNF-α antibodies reduce the cleavage of 
PARP triggered by supernatant from infected SW13 cells at 48 h post infection. However this 
needs to be investigated further, since the neutralisation was not complete, most probably 
because we could not neutralise all TNF-α and/or because other molecules are involved in 
triggering the extrinsic pathway. Previous studies have shown that key molecules in CCHF 
progression seem to be cytokines such as TNF-alpha. In an animal model study, it has been 
also demonstrated the elevated levels of TNF-alpha concentrations are correlated to disease 
severity (Ergonul, Tuncbilek et al. 2006, Papa, Bino et al. 2006, Bente, Alimonti et al. 2010).  
We have previously demonstrated that CCHFV has the ability to interfere with host Type I IFN 
response (REF). In Paper I we showed that IRF-3 nuclear translocation and induction of ISGs 
are delayed in CCHFV-infected cells. IRF-3 is a cytoplasmic protein that upon activation is 
translocated to the nucleus and plays an important role in the induction of IFNs during viral 
infection. However, it is not known whether this delay indicates that CCHFV is unable to 
stimulate a strong immune response through RIG-I activation, upstream of IRF-3, or is a result 
of an unidentified IFN antagonist (Habjan, Andersson et al. 2008). 
IRF-3 also seems to play an essential role in mediating induction of apoptotic pathways. In 
addition to acting as a transcription factor for the induction of antiviral genes, IRF-3 is also 
involved in cell death by indirect triggering caspase activation (Chattopadhyay, Marques et al. 
2010). In Paper II we showed that CCHFV has strategies to interplay or interfere with apoptotic 
molecular signalling pathways through Bax.  
It has been reported previously that IRF-3 also has the ability to act as a pro-apoptotic protein, 
independent of its role as a transcription factor, i.e. that IRF-3 activation pathways make it 
competent as either a transcription factor or an apoptotic factor (Chattopadhyay, Marques et 
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al. 2010). Those authors have also shown that the activated IRF-3 induces mitochondrial-
dependent apoptosis through Bax, serving as a connection between the innate and the 
apoptotic response. 
As it has been mentioned Paper I, CCHFV can delay activation of IRF-3 and can thereby 
escape the early interferon response but also escape of early activation of IRF3 can delay the 
initiation of apoptosis in concert with N, which we showed suppresses or delay Bax activity 
(Paper III).  
These data together demonstrate that CCHFV has developed strategies to interplay and 
interfere with apoptosis and the early innate immune response. We believe these results 
presented in this thesis will shed a light on the molecular mechanism of CCHFV pathogenesis. 
In summary, the results presented in Papers I to IV have revealed a complex interplay 
between CCHFV and the regulation of apoptosis in infected cells. In early infection, CCHFV 
seems to down-regulate certain apoptotic signalling leading to an anti-apoptotic stage. 
Interestingly, the CCHFV N protein plays a role in this down-regulation while itself could be 
cleaved by the activated caspase 3 because of a DEVD motif, which is buried in the 
superhelical form of N but becomes exposed upon conformational change resulting from the 
binding of short RNAs. However, in late infection, the extrinsic apoptotic pathway becomes 
activated probably due to the induction of TNF-α and other cytokines by CCHFV infected 
cells. To this end, we have yet been able to understand how the balance of apoptosis and 
cleavage of N impact on CCHFV replication and pathogenesis. Further work is therefore 
needed to map the network of viral-host interactions in CCHFV infection and to define the 
importance of such interactions for the regulation of innate immune response and induction 
of viral pathogenesis in suitable animal models. 
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CONCLUSIONS 
 
 In this thesis we  
 
- Demonstrated that replicating CCHFV has the ability to delay the early Type I IFN 
response in host-probably by intefering with IRF-3 pathway ( paper I). 
 
 
- Found by examination of the primary structure of CCHFV N a potential motif for 
caspase cleavage (DEVD) at position 266-269 of the nucleocapsid (N) protein. 
Comparison with available sequences of S segment of CCHFV in the gene bank 
revealed that this motif was conserved in all available strainst. The cleavage process 
of N seems to be caspase-3-dependent and caspase activation do not favour the 
production of CCHF progeny virus (paper II). 
 
- We demonstrated that the conserved caspase-3 cleavage site is located at the top, 
α12-α13 loop, of the stalk domain. Our results suggest the interaction between N 
and RNA regulates the conformation of N and determines if the DEVD motif is 
exposed for caspase cleavage (paper III). 
 
 
- Demonstrated that caspase activation are supressed early during CCHFV relication 
cycle. Caspase activation are regulated at mitochondria level early during CCHF 
infection. At late post CCHF infection apoptosis are most probably induced by pro-
inflammatory factors, which in turn activates the extrinsic apoptotic pathway and that 
pro-inflammatory mediators might induce extrinsic pathways as a secondary effect 
(paper IV) 
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